Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 461

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 461
---
                                              |     |                   |             |   |     |               |             |   |     |             |            |   |     |       |     |             |  73,880,474 |   |     | -M    |     |           |             |   |
| Foreign currency translation/Accumulated other comprehensive loss                                                                                                                                                                            |     |                   |  (1,093,528 | ) |     |               |     108,853 |   |     |             |          — |   |     |       |     |             |    (108,853 | ) |     | -M    |     |           |  (1,093,528 | ) |
| Total shareholders’ (deficit) equity                                                                                                                                                                                                         |     |                   |  (7,996,088 | ) |     |               |   1,406,361 |   |     |             |  2,553,699 |   |     |       |     |             |  24,281,419 |   |     |       |     |           |  20,246,391 |   |
| Total Liabilities and Shareholders’ (Deficit) Equity                                                                                                                                                                                         |     | $                 |     903,757 |   |     | $             |   2,233,125 |   |     | $           |  2,553,699 |   |     |       |     | $           |  17,348,461 |   |     |       |     | $         |  23,039,042 |   |

The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

265

Unaudited Pro Forma Condensed Combined Statement of Operations and Other Comprehensive Loss

|                                                                                                               |     | For the Twelve Months Ended December 31, 2024 |            |       |     |                  |              |      |     |             |           |   |     |       |     |           |            |   |
|:--------------------------------------------------------------------------------------------------------------|:----|:----------------------------------------------|-----------:|:------|:----|:-----------------|-------------:|:-----|:----|:------------|----------:|:--|:----|:------|:----|:----------|-----------:|:--|
|                                                                                                               |     | Kadimastem                                    
 Ltd.                                          |            |       |     | NLS              
 Pharmaceuticals, 
 Ltd.             |